PRJNA665109
NEOSTAR Study: Non-small cell lung cancer treated with nivolumab or nivolumab plus ipilimumab
Phase 2 randomized study of neoadjuvant nivolumab or nivolumab plus ipilimumab followed by surgery in patients with resectable NSCLC using major pathologic response as primary endpoint (NCT03158129)